IRIS
PASQUINUCCI, Lorella Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.859
AS - Asia 2.932
EU - Europa 2.684
AF - Africa 494
SA - Sud America 477
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.458
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.669
SG - Singapore 1.464
IT - Italia 1.201
CN - Cina 962
IE - Irlanda 415
BR - Brasile 412
CI - Costa d'Avorio 310
UA - Ucraina 279
RU - Federazione Russa 244
DE - Germania 167
CA - Canada 154
SN - Senegal 119
KR - Corea 117
VN - Vietnam 114
GB - Regno Unito 58
IN - India 53
JP - Giappone 52
ES - Italia 46
FR - Francia 46
SE - Svezia 40
FI - Finlandia 35
NL - Olanda 33
ID - Indonesia 30
PL - Polonia 30
MX - Messico 25
BD - Bangladesh 24
HK - Hong Kong 23
BE - Belgio 21
ZA - Sudafrica 20
TR - Turchia 19
AR - Argentina 18
AT - Austria 14
BJ - Benin 13
EC - Ecuador 13
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
UZ - Uzbekistan 11
AU - Australia 10
CZ - Repubblica Ceca 10
IR - Iran 9
PK - Pakistan 9
GR - Grecia 8
IQ - Iraq 8
VE - Venezuela 8
CO - Colombia 7
HU - Ungheria 7
LT - Lituania 7
MA - Marocco 7
TN - Tunisia 7
CL - Cile 6
IL - Israele 5
KE - Kenya 5
LB - Libano 5
PY - Paraguay 5
BG - Bulgaria 4
EG - Egitto 4
NG - Nigeria 4
PE - Perù 4
SA - Arabia Saudita 4
DO - Repubblica Dominicana 3
DZ - Algeria 3
JM - Giamaica 3
KZ - Kazakistan 3
RS - Serbia 3
UY - Uruguay 3
BB - Barbados 2
GE - Georgia 2
NP - Nepal 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
EU - Europa 1
IM - Isola di Man 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
SL - Sierra Leone 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 13.458
Salva come PNG Salva come JPEG
Città #
Dallas 1.826
Singapore 791
Santa Clara 777
Chandler 591
Houston 477
Dublin 412
Catania 367
Chicago 336
Abidjan 310
Ashburn 295
Jacksonville 286
Hefei 229
Boardman 188
Beijing 163
Dakar 119
Seoul 117
Nanjing 116
Cambridge 110
Andover 109
Lawrence 109
Los Angeles 104
Civitanova Marche 98
Toronto 95
Moscow 72
Council Bluffs 62
Bremen 60
Wilmington 57
New York 55
Rome 54
Des Moines 50
San Mateo 47
Buffalo 46
The Dalles 45
Tokyo 45
Columbus 39
São Paulo 39
Naples 38
Grafing 36
Munich 35
Shenyang 35
Ho Chi Minh City 34
Nanchang 33
Saint Petersburg 32
Changsha 26
Messina 26
Jiaxing 25
Ottawa 25
Hanoi 23
Hebei 21
Warsaw 21
Brussels 20
Hong Kong 20
Denver 19
Tianjin 19
Jakarta 18
Milan 18
Brooklyn 17
Pune 17
Rio de Janeiro 17
Atlanta 16
Falls Church 15
Montreal 15
San Giovanni la Punta 14
Seattle 14
Turku 14
Amsterdam 13
Cotonou 13
San Francisco 13
Johannesburg 12
Palermo 12
Chennai 11
Dong Ket 11
Helsinki 11
Augusta 10
Lappeenranta 10
London 10
Ningbo 10
Norwalk 10
Phoenix 10
Poplar 10
Pozzallo 10
Stockholm 10
Jinan 9
Madrid 9
Mexico City 9
Paris 9
Rimini 9
Sala Baganza 9
Salerno 9
Ardabil 8
Bari 8
Belo Horizonte 8
Bologna 8
Haiphong 8
Leawood 8
Paternò 8
Ankara 7
Brno 7
Budapest 7
Curitiba 7
Totale 9.692
Salva come PNG Salva come JPEG
Nome #
Targeting histone deacetylase 1: Inhibition and activation as promising therapeutic strategies for diverse disorders 403
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 396
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 274
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 203
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 173
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 173
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 172
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells 164
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 160
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 146
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 144
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 143
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 135
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 131
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 130
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 129
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 124
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 122
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 121
Design of Small Molecules for Oncological and Neurodegenerative Diseases 120
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties 120
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 118
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 118
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 116
Benzomorphan-based opioid ligands with mixed m agonist/d antagonist activity 114
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 113
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 112
Intercellular communication and ion channels in neuropathic pain chronicization 112
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 111
Bivalent opioid-peptides synthesized from mu-selective monomers display preferential selectivity for delta-receptors 110
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 110
Analgesici oppioidi: nuove opportunità nella terapia del dolore 109
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 108
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 108
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 107
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 107
From plant to bench: natural products as source for analgesic drug development. 107
MOR/DOR targeting: an useful strategy in pain management 106
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 104
Bivalent opioid peptides synthesized from μ selective monomers display preferential selectivity for δ receptors 103
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 101
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 101
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 101
CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites 101
Design and synthesis of trans-decahydroisoquinoline derivatives as new tramadol-like ligands 99
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 99
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 99
Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites 98
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 97
Multitarget opioid ligands in pain relief: New players in an old game 96
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 96
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 96
SYNTHESIS OF (+)-(1'R,2'S) AND (1'S,2'R)-6,11-DIMETHYL-1,2,3,4,5,6-HEXAHYDRO-3-[[2'-(ALKOXYCARBONYL)-2'-PHENYLCYCLOPROPYL]METHYL]-2,6-METHANO-3-BENZAZOCIN-8-OL. COMPARISON OF THE AFFINITIES FOR SIGMA 1 AND OPIOID RECEPTORS WITHIN THE DIASTEREOISOMERIC MPCB AND CCB 95
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 94
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 93
CCB - A novel analog of MPCB with high binding affinity and specific kappa opioid receptor agonist 92
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 92
Correction to Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 91
Non-peptide ligands for opioid receptors. Design of kappa-specific agonists 91
Nonpeptide Analogues of Dynorphin A(1-8): Design, Synthesis, and Pharmacological Evaluation of k-Selective Agonists 91
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 90
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 90
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 89
Progress in the development of more effective and safer analgesics for pain management 88
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 86
Analoghi non-peptidici della dinorfina A(1-8): progettazione, sintesi e valutazione farmacologica di agonisti ad elevata selettività Kappa. 86
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 85
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 85
Dual-target ligands and pain: our experience 84
Analgesici oppioidi 84
Differential scanning calorimetry approach to investigate the transfer of the multitarget opioid analgesic LP1 to biomembrane model 84
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 83
Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partition 83
In-vitro evaluation of a new benzomorphan-based ligand 83
Design, Synthesis and biological evaluation of hybrid MOR agonist/ HDACi molecules as potential therapeutic agents for chronic pain treatment 82
From agonist to antagonist profile in LP1 analogues through the introduction of different N-substituents in benzomorphan-based ligands 82
Multitarget opioid ligands as suitable candidates for pain management Pharmacolgical fingerprint of the benzomorphan-based opioid compound LP1 82
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 82
Design and Synthesis of Tetrahydropyrrolo[3,4‐c]Pyrazole Sigma‐1 Receptor Ligands 81
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 81
New developments in opioid receptors ligands 80
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 80
Evaluation of N-substitution in 6,7-benzomorphan compounds 80
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 79
Idebenone: Novel strategies to improve its systemic and local efficacy 79
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 78
Development of new benzomorphan LP1 analogues 77
New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands 77
Opioid multiple ligands 76
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 75
Design, synthesis and biological evaluation of MOR agonist/HDACi hybrid compounds: a new potential therapeutic strategy for persistent pain management 75
The blockade of NOP receptor in the vlPAG reduces the development of tolerance to opioid-induced antinociception in rats 75
Resveratrol-loaded lipid nanocarriers: Correlation between in vitro occlusion factor and in vivo skin hydrating effect 75
Novel sigma 1-antagonists with cis-(+)-normetazocine scaffold: synthesis, molecular modeling, and antinociceptive effect 74
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 74
Synthesis and Pharmacological Evaluation of Peptidomimetic of the Kappa-Opioid Receptors 73
Synthesis of substituted pyrimidines, pyrazole[3,4-d]pyrimidines and imidazo[4,5-d]pyrimidines and evaluation of their antifungal activity 73
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics for Pain Treatment 72
Specific kappa opioid receptor agonists 72
Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic connexin 43 in an animal model of neuropathic pain 72
Totale 10.905
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.754
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021335 0 0 0 0 0 18 64 6 85 13 114 35
2021/2022934 100 105 9 24 135 11 120 34 84 26 36 250
2022/20231.774 140 97 29 239 132 267 6 344 365 35 80 40
2023/20241.092 55 138 51 40 56 262 67 111 8 30 188 86
2024/20253.397 83 520 150 227 665 426 231 137 219 263 226 250
2025/20264.528 473 387 2.055 513 1.066 34 0 0 0 0 0 0
Totale 13.795